Als Therapy Development Institute

Biogen Ma Inc.

Biogen Idec Ma Inc.

John Monteith Lincecum

Alan Gill

Fernando G Vieira

Steven N Perrin

Cynthia A Gill

Bingbing Jiang

Linda C Burkly

Timothy Zheng

Kyungmin Hahm

Steve Perrin

Steven Perrin

Anti-human CD40L antibodies engineered to lack the ability to activate platelets and methods for treating patients having a CD40L-associated disease.

Anti-CD40L antibodies and methods for treating CD40L-related diseases or disorders

Anti-CD40L antibodies

Methods of treating a CD40L associated disease or disorder by administering anti-CD40L antibodies

Methods of treating neuronal disorders, such as mechanical neuronal traumas and neurodegenerative disorders, with TWEAK or a TWEAK receptor blocking agents are presented.

Treating neurological disorders

Disclosed are methods for treating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis, Alzheimer's Disease Parkinson's Disease, Myasthenia Gravis, Multifocal Motor Neuropathy, Primary Lateral Sclerosis, Spinal Muscular Atrophy, Kennedy's Disease, and Spinocerebellar Ataxia.

Method for the treatment of neurodegenerative diseases

Methods and therapeutic compositions are disclosed for treating neurodegenerative disorders and, in particular Amyotrophic Lateral Sclerosis, using sphingosine1-phosphate receptor modulators, such as fingolimod or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

Targeting of T-lymphocytes to treat amyotrophic lateral sclerosis

Methods and therapeutic agents are disclosed for treating neurodegenerative disorders by depletion of CD8 positive T cells by using antibodies, FAb fragments of antibodies or similar agents that sequester, neutralize or deplete the CD8+ cytotoxic T cells.

Targeting of CD8+ T-lymphocytes to treat neurodegenerative diseases

Disclosed are methods for treating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis, Alzheimer's Disease, Parkinson's Disease, Myasthenia Gravis, Multifocal Motor Neuropathy, Primary Lateral Sclerosis, Spinal Muscular Atrophy, Kennedy's Disease, and Spinocerebellar Ataxia, by administration of a compound that blocks the interaction of CD40 and CD40L.

Growing community of inventors

Jamaica Plain, MA, United States of America

John Monteith Lincecum